INTRODUCTION: Children are less likely to have severe acute COVID-19, but cases of pediatric multisystem inflammatory syndrome (PIMS) with possible temporal association with previous SARS-CoV-2 infection have been described. OBJECTIVES: Non-systematic review of the literature on epidemiology, pathophysiology, diagnosis, and treatment of PIMS. SOURCE OF DATA: PubMed database, scientific documents of the Brazilian Society of Pediatrics, World Health Organization, Centers for Disease Control and Prevention (CDC), and Royal College of Pediatrics and Child Health. SUMMARY OF FINDINGS: PIMS shares characteristics with Kawasaki disease, toxic shock syndrome, bacterial sepsis and cytokine storm syndrome. It is more frequent in Afrodescendants and Hispanics, schoolchildren and adolescents, and in males. It occurs 2-4 weeks after SARS-CoV-2 infection. Pathophysiology involves direct effects of the virus and/or post-COVID-19 immune dysregulation. The clinical presentation is heterogeneous, fever being very frequent, followed by gastrointestinal, cardiovascular, respiratory, neurological, and renal manifestations. Thorough anamnesis and physical examination, as well as complementary exams to assess inflammatory process, organ involvement and the relationship with SARS-CoV-2 infection (RT-PCR and serology), are essential. Diagnostic criteria proposed by the CDC and WHO support the diagnosis. Treatment must be coordinated by a team of specialists, and directed to inflammatory and organic manifestations. CONCLUSIONS: PIMS is characterized by a broad clinical spectrum, with fever, gastrointestinal, neurological manifestations, shock, and myocardial dysfunction. It requires a high degree of suspicion for early treatment and prevention of potential cardiovascular, respiratory, renal, and neurological complications.